Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years
Authors
Keywords
-
Journal
BRITISH JOURNAL OF DERMATOLOGY
Volume 166, Issue 4, Pages 861-872
Publisher
Wiley
Online
2012-02-23
DOI
10.1111/j.1365-2133.2012.10901.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis
- (2011) Craig Leonardi et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies
- (2011) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris
- (2011) R. Gniadecki et al. BRITISH JOURNAL OF DERMATOLOGY
- Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis
- (2011) Vito Di Lernia et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials
- (2011) Mark Lebwohl et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials
- (2011) Kenneth B. Gordon et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL
- (2011) Kenneth Gordon et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy
- (2010) K. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- The Impact of Methodological Approaches for Presenting Long-Term Clinical Data on Estimates of Efficacy in Psoriasis Illustrated by Three-Year Treatment Data on Infliximab
- (2010) M. Papoutsaki et al. DERMATOLOGY
- Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations
- (2010) Mark Lebwohl et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population
- (2010) Kim A. Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
- (2010) Christopher E.M. Griffiths et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antinuclear antibodies associate with loss of response to antitumour necrosis factor-α therapy in psoriasis: a retrospective, observational study
- (2009) A.E. Pink et al. BRITISH JOURNAL OF DERMATOLOGY
- Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial
- (2009) M. Lebwohl et al. BRITISH JOURNAL OF DERMATOLOGY
- Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
- (2009) Eihab A. Alwawi et al. Dermatologic Therapy
- Population-Based Exposure-Efficacy Modeling of Ustekinumab in Patients With Moderate to Severe Plaque Psoriasis
- (2009) Honghui Zhou et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy
- (2008) R.M.R. Hearn et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
- (2008) Craig L Leonardi et al. LANCET
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
- (2008) Kim A Papp et al. LANCET
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
- (2007) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now